Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Toxicol Appl Pharmacol. 2013 Oct 3;273(2):10.1016/j.taap.2013.09.021. doi: 10.1016/j.taap.2013.09.021

Figure 1.

Figure 1

EGCG inhibits human skin cancer cell viability. (A) Treatment of human skin cancer cells (A431 and SCC13) with EGCG inhibits cell viability in a dose- and time-dependent manner. Cell viability was determined by MTT assay at 24, 48 and 72 h. The data on cell viability are expressed in terms of percent of control cells (non-EGCG treated) as the mean ± SD of 5 replicates. (B) EGCG enhances death of human skin cancer cells. Cell death was determined using trypan blue dye exclusion assay. The data on cell death are presented as the mean percent of dead cells from three independent experiments ± SD vs control group. Significant difference vs. control group, *P<0.001; P<0.01. (C) Cells were treated with various concentrations of EGCG for 48 h and cell lysates were used to detect the levels of cyclins and cyclin-dependent kinases using western blot analysis. β-actin served as the loading control.